Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials.

Mike Dennis, Jad Othman, Joanna Canham, Ian Thomas, Sean Johnson, Nick Telford, Beth Harrison, Jeyaprakash Ramachandran, James Cavenagh, Claire Arnold, Claus Marcher, Richard Kelly, Mhairi Copland, Alan Burnett, Richard Dillon, Nigel Russell

Blood (2025) 146 (Supplement 1): 3435.

https://doi.org/10.1182/blood-2025-3435

Published: 2025

Journal Articles

Redefining the myeloid disease continuum: Machine learning–based development and validation of an integrated multimodal classification of myeloid neoplasms

Yu-Hung Wang, Kristian Gurashi, Chien-Chin Lin, Carmelo Gurnari, Hussein Awada, Adrian Mosquera, Manuel Perez Encinas, Donal McLornan, Andrius Zucenka, Talha Badar, Bor-Sheng Ko, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien, Jaroslaw Maciejewski, Nick Telford, Kiran Batta, Daniel Wiseman

Blood (2025) 146 (Supplement 1): 4347.

https://doi.org/10.1182/blood-2025-4347

Published: 2025

Journal Articles

Population Based Study of Cytogenetic Abnormalities in Addition to Philadelphia (Ph) Chromosome in Patients with Chronic Myeloid Leukaemia (CML) and Impact on Survival

Jo Tomlins, MSc, Nick Telford, PhD, Mike Dennis, FRCPath, Tim Somervaille, FRCPath, Adrian Bloor, PhD FRCPath, Jim Cavet, FRCPath, Mike Green, PhD, Sven Armin Sommerfeld, MRCP, John Murray, RGN, MSc, Samar Kulkarni, FRCPath

Blood (2014) 124 (21): 4567.

https://doi.org/10.1182/blood.V124.21.4567.4567

Published: 2014

Journal Articles

Response of ETV6-FLT3 –positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3

Christoph Walz, Philipp Erben, Michael Ritter, Adrian Bloor, Georgia Metzgeroth, Nick Telford, Claudia Haferlach, Torsten Haferlach, Stefan Gesk, Joannah Score, Wolf-Karsten Hofmann, Andreas Hochhaus, Nicholas C. P. Cross, Andreas Reiter

Blood (2011) 118 (8): 2239–2242.

https://doi.org/10.1182/blood-2011-03-343426

Published: 2011

Includes: Supplemental data

Journal Articles

Recurrent Fusion of PCM1 to JAK2 in Atypical Chronic Myeloid Leukemia and Acute Leukemia Associated with the t(8;9)(p21-22;p23-24).

Andreas Reiter, Christoph Walz, Ann Watmore, Claudia Schoch, Ilona Blau, Nick Telford, Shilani Aruliah, John Yin, Danny Vanstraelen, Helen Barker, Peter Taylor, Aisling O’Driscoli, Brigitte Schlegelberger, Ute Berger, Andreas Hochhaus, Rüdiger Hehlmann, Andrew Chase, Nicholas C.P. Cross

Blood (2004) 104 (11): 2963.

https://doi.org/10.1182/blood.V104.11.2963.2963

Published: 2004

Journal Articles

Deletions of the derivative chromosome 9 do not account for the poor prognosis associated with Philadelphia-positive acute lymphoblastic leukemia

Alistair G. Reid, Brian J. P. Huntly, Eveline Hennig, Dietger Niederwieser, Lynda J. Campbell, Nick Bown, Nick Telford, Helen Walker, Colin D. Grace, Michael W. Deininger, Anthony R. Green, Elisabeth P. Nacheva

Blood (2002) 99 (6): 2274–2275.

https://doi.org/10.1182/blood.V99.6.2274

Published: 2002

Journal Articles

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia

Brian J. P. Huntly, Alistair G. Reid, Anthony J. Bench, Lynda J. Campbell, Nick Telford, Patricia Shepherd, Jeff Szer, H. Miles Prince, Paul Turner, Colin Grace, Elizabeth P. Nacheva, Anthony R. Green

Blood (2001) 98 (6): 1732–1738.

https://doi.org/10.1182/blood.V98.6.1732

Published: 2001

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials.

Redefining the myeloid disease continuum: Machine learning–based development and validation of an integrated multimodal classification of myeloid neoplasms

Population Based Study of Cytogenetic Abnormalities in Addition to Philadelphia (Ph) Chromosome in Patients with Chronic Myeloid Leukaemia (CML) and Impact on Survival

Response of ETV6-FLT3 –positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3

Recurrent Fusion of PCM1 to JAK2 in Atypical Chronic Myeloid Leukemia and Acute Leukemia Associated with the t(8;9)(p21-22;p23-24).

Deletions of the derivative chromosome 9 do not account for the poor prognosis associated with Philadelphia-positive acute lymphoblastic leukemia

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials.

Redefining the myeloid disease continuum: Machine learning–based development and validation of an integrated multimodal classification of myeloid neoplasms

Population Based Study of Cytogenetic Abnormalities in Addition to Philadelphia (Ph) Chromosome in Patients with Chronic Myeloid Leukaemia (CML) and Impact on Survival

Response of ETV6-FLT3 –positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3

Recurrent Fusion of PCM1 to JAK2 in Atypical Chronic Myeloid Leukemia and Acute Leukemia Associated with the t(8;9)(p21-22;p23-24).

Deletions of the derivative chromosome 9 do not account for the poor prognosis associated with Philadelphia-positive acute lymphoblastic leukemia

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only